John Parkinson

Roche’s tocilizumab did not improve clinical status in hospitalized adult patients with severe COVID-19 associated pneumonia.

One cardiologist speaks about what she witnessed in her NYC hospital including how the virus can be multi-organ and the development of COVID-19 diagnostic protocols.

The federal agency gives approval for technology company’s test that supports unmonitored testing.

The randomized, placebo-controlled trial will be enrolling 30000 American adults to test the safety and efficacy of the codeveloped vaccine.

Researchers have identified which olfactory cell types are vulnerable to the virus.

FDA reissues LabCorp’s existing diagnostic test for EUA, which opens up testing protocol for anyone.

The NIAID director offered nuanced advice on kids going back to school, getting to a baseline in the US, and how to prepare for the upcoming influenza season combined with COVID-19.

A small study reports no mother-to-newborn transmission of virus.

In this second installment of his interview, Howard Koh, MD, MPH, discusses the importance of providers and health care workers wearing face masks during their interactions with patients.

HHS is securing Pfizer and BioNTech’s BNT162 vaccine as soon as FDA approves.

A former Assistant Secretary of Health calls upon both to consider how a face mask mandate could mitigate transmission and mortality.

The FDA clears way for next phase for abivertinib to treat hospitalized patients.

This was seen in patients who were receiving either invasive mechanical ventilation or oxygen.

Luminex Receives FDA Emergency Use Authorization for its xMAP SARS-CoV-2 Multi-Antigen IgG Assay.

In a small Italian study, a majority of patients who were hospitalized and recovered from the virus, had lingering symptoms and many had a “worsened quality of life.”

A paper examines how these droplets are transmitted and ways to protect these providers from COVID-19.

Rajiv Dhand, MD, discusses the importance of everyone wearing face masks including health care workers seeing patients outside the hospital setting.

In the second segment of the interview, Gilead’s Gelezinuas and SenGupta discuss the areas of unmet HIV therapy needs, cure research, and the benefits of a virtual conference.

Pfizer and BioNTech were given approval by the federal agency to expedite their work on investigational vaccines.

Gilead provides some important information on this investigational therapy.

Biopharmaceutical companies create nearly $1 billion fund to aid much needed pipeline for antimicrobial resistance.

A small study shows a majority of HIV patients open to both starting ART and follow-up telehealth appointments.

In a large study, an examination of patterns of use.

In developing countries with overcrowded hospitals, community pharmacies can relive burden, help HIV patients.

Uncovering interesting findings regarding patients' PrEP regimen.

Time interval goes down by 3 months in 3 year period.

Small study shows HIV patients not at a greater risk for worse outcomes.

With insufficient HIV diagnosis testing in that country, this novel testing could help it reach part of its UNAIDS 90-90-90 targets.

In low-level HIV-1 viraemia patients, this strategy demonstrated viral suppression in more than half of a study's participants.

Carey Hwang, MD, PhD, executive director and product development lead, Global Clinical Development of Infectious Disease at Merck spoke with Contagion® regarding the therapies and went further into depth about the studies.